Ipsen SA (IPN):企業の財務・戦略的SWOT分析

◆英語タイトル:Ipsen SA (IPN) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH15876FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:64
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥41,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Ipsen SA (IPN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Ipsen SA (Ipsen) is a global specialty biopharmaceutical company that manufactures and distributes drugs for the treatment of cancer and rare and neurological diseases. The company develops and commercializes novel medicines in cancer, neuroscience and rare diseases. It also offers products to treat gastrointestinal disorders, neurodegenerative pathologies and rheumatology diseases. Ipsen sells its drugs through distributors and directly to hospitals in few countries. It main research and development facilities in Paris-Saclay, France; Oxford, the UK; and Cambridge, the US. The company offers products in Europe, North America, Asia and rest of the world. Ipsen is headquartered in Paris, France.

Ipsen SA Key Recent Developments

Apr 01,2021: Fusion Pharmaceuticals Announces Closing of Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen
Feb 11,2021: Ipsen delivered sales growth and margin expansion in 2020 – Focused on executing new strategy and delivering financial objectives in 2021
Jan 20,2021: Ipsen appoints Gwenan White as executive Vice President, Communications and Public Affairs
Dec 01,2020: Ipsen highlights new strategic priorities and provides mid-term financial outlook
Oct 22,2020: Ipsen delivers sales growth in the first nine months of 2020 despite the impact of COVID-19 and confirms its 2020 full year guidance

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Ipsen SA – Key Facts
Ipsen SA – Key Employees
Ipsen SA – Key Employee Biographies
Ipsen SA – Major Products and Services
Ipsen SA – History
Ipsen SA – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Ipsen SA – Business Description
Business Segment: Consumer Healthcare
Overview
Performance
Business Segment: Other Revenues
Performance
Business Segment: Specialty Care
Overview
Performance
Geographical Segment: Major Western European Countries
Target Markets
Performance
Geographical Segment: North America
Performance
Geographical Segment: Other European Countries
Target Markets
Performance
Geographical Segment: Rest of the World
Target Markets
Performance
R&D Overview
Ipsen SA – Corporate Strategy
Ipsen SA – SWOT Analysis
SWOT Analysis – Overview
Ipsen SA – Strengths
Ipsen SA – Weaknesses
Ipsen SA – Opportunities
Ipsen SA – Threats
Ipsen SA – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Ipsen SA, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 11, 2021: Ipsen delivered sales growth and margin expansion in 2020 – Focused on executing new strategy and delivering financial objectives in 2021
Jan 20, 2021: Ipsen appoints Gwenan White as executive Vice President, Communications and Public Affairs
Dec 01, 2020: Ipsen highlights new strategic priorities and provides mid-term financial outlook
Oct 22, 2020: Ipsen delivers sales growth in the first nine months of 2020 despite the impact of COVID-19 and confirms its 2020 full year guidance
Oct 05, 2020: FAS RUSSIA: Ipsen unreasonably refused Biotek to conclude contract for medicine supply
Sep 25, 2020: Ipsen appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer
Jul 30, 2020: Ipsen presents its half year 2020 results and reinstates guidance for full year 2020
Jul 01, 2020: David Loew joins Ipsen as CEO
Jun 08, 2020: Ipsen demonstrates continued commitment to rare diseases with eight abstracts accepted at ENDO 2020 published in the Journal of the Endocrine Society
May 29, 2020: Ipsen appoints David Loew as chief executive officer
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Ipsen SA, Key Facts
Ipsen SA, Key Employees
Ipsen SA, Key Employee Biographies
Ipsen SA, Major Products and Services
Ipsen SA, History
Ipsen SA, Subsidiaries
Ipsen SA, Joint Venture
Ipsen SA, Key Competitors
Ipsen SA, Ratios based on current share price
Ipsen SA, Annual Ratios
Ipsen SA, Annual Ratios (Cont...1)
Ipsen SA, Annual Ratios (Cont...2)
Ipsen SA, Interim Ratios
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Ipsen SA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Ipsen SA (IPN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Pabulum Limited:企業の戦略・SWOT・財務分析
    Pabulum Limited - Strategy, SWOT and Corporate Finance Report Summary Pabulum Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • T2 Biosystems Inc (TTOO):企業の財務・戦略的SWOT分析
    Summary T2 Biosystems Inc (T2 Biosystems) is a provider of clinical diagnostic products in the field of in vitro diagnostics. The company’s T2 magnetic resonance technology allows direct detection in complex samples such as whole blood, serum, plasma, sputum and urine. T2 Biosystems offers T2HemoSta …
  • Edgars Stores Limited:企業の戦略・SWOT・財務情報
    Edgars Stores Limited - Strategy, SWOT and Corporate Finance Report Summary Edgars Stores Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • InMed Pharmaceuticals Inc (IN):医療機器:M&Aディール及び事業提携情報
    Summary InMed Pharmaceuticals Inc (InMed), formerly Cannabis Technologies Inc, is a pre-clinical stage biopharmaceutical company which develops, produces and markets plant cannabinoid based medicines. The company's pipeline products include INM-750, INM-405, and INM-085. Its products finds applicati …
  • Atmos Energy Corp (ATO):石油・ガス:M&Aディール及び事業提携情報
    Summary Atmos Energy Corp (Atmos Energy) is a fully-regulated natural gas distributor. Together with its subsidiaries, the company delivers natural gas through regulated sales and transportation arrangements to residential, commercial, public authority and industrial customers.The company is also in …
  • Navitas Limited (NVT):企業の財務・戦略的SWOT分析
    Navitas Limited (NVT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Martifer SGPS SA (MAR):企業の財務・戦略的SWOT分析
    Martifer SGPS SA (MAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Definiens AG:医療機器:M&Aディール及び事業提携情報
    Summary Definiens AG (Definiens), a subsidiary of AstraZeneca Plc, is a healthcare technology company that offers image analysis and data mining solutions. The company offers products such as tissue studio, developer, image miner, server, architect and viewer, among others. Its services include cons …
  • CG Power and Industrial Solutions Ltd (CGPOWER):企業の財務・戦略的SWOT分析
    CG Power and Industrial Solutions Ltd (CGPOWER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …
  • Anglian Group Limited:企業の戦略・SWOT・財務情報
    Anglian Group Limited - Strategy, SWOT and Corporate Finance Report Summary Anglian Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • International Consolidated Airlines Group, S.A.:企業の戦略・SWOT・財務情報
    International Consolidated Airlines Group, S.A. - Strategy, SWOT and Corporate Finance Report Summary International Consolidated Airlines Group, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, o …
  • Eaton Corporation Plc (ETN):企業の財務・戦略的SWOT分析
    Eaton Corporation Plc (ETN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Exelixis Inc (EXEL):製薬・医療:M&Aディール及び事業提携情報
    Summary Exelixis Inc (Exelixis) is a biopharmaceutical company that focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company has three product candidates: Cometriq (Cabozantinib), an inhibitor of multiple receptor tyrosine kinases; Cabomet …
  • Mechel:企業のM&A・事業提携・投資動向
    Mechel - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mechel Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital rais …
  • Quest Diagnostics Inc (DGX):製薬・医療:M&Aディール及び事業提携情報
    Summary Quest Diagnostics Inc (Quest Diagnostics) is a provider of diagnostic information services to patients and physicians through a chain of laboratories and company-owned patient service centers. It offers comprehensive range of services including clinical testing with gene-based and other esot …
  • LifePoint Health Inc (LPNT):製薬・医療:M&Aディール及び事業提携情報
    Summary LifePoint Health Inc (LifePoint) is a healthcare service provider which operates community hospitals, physician practices, outpatient centers, post-acute facilities and regional health systems. The company along with its subsidiaries delivers a range of medical and surgical services to non-u …
  • Turboatom (TATM):企業の財務・戦略的SWOT分析
    Turboatom (TATM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • T3D Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary T3D Therapeutics Inc (T3D) is a developer of solutions for the treatment of Alzheimer’s disease and Mild Cognitive Impairment. The company’s pipeline product include T3D-959, an optimal disease remedial therapeutic for the treatment of Alzheimer’s disease. It provides a potential to improve …
  • WPX Energy, Inc.:企業の戦略・SWOT・財務情報
    WPX Energy, Inc. - Strategy, SWOT and Corporate Finance Report Summary WPX Energy, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Taiga Building Products Ltd (TBL):企業の財務・戦略的SWOT分析
    Taiga Building Products Ltd (TBL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆